Montreal cognitive assessment domain-specific and clinical predictors of postoperative delirium in elderly gastrointestinal cancer patients
Surgery Today · 2025
DOI: 10.1007/s00595-025-03171-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery Today, 2025. Verfasst von Haruna Yamaguchi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Technology, Sakai City Medical Center, Sakai, Japan. Hauptthemen laut MEDLINE: Delirium, Postoperative Complications, Gastrointestinal Neoplasms, Mental Status and Dementia Tests. Die Arbeit nennt 31 Literaturangaben.
Themen: Onkologische Pflege, Delir
Abstract (Originalsprache)
PURPOSES: Postoperative delirium (POD) is a serious complication in elderly patients undergoing gastrointestinal (GI) cancer surgery. This study aimed to identify the perioperative risk factors for POD, focusing on domain-specific cognitive function. METHODS: We retrospectively analyzed patients ≥ 65 years old who underwent GI cancer surgery and preoperative geriatric screening. POD was assessed using the Delirium Symptomatology Test. Cognitive domains were evaluated using the Japanese Montreal Cognitive Assessment (MoCA-J). A receiver operating characteristic (ROC) analysis identified the most predictive domain combination and compared its discriminative performance with that of conventional tools. Independent associations with POD were examined using Firth's logistic regression. RESULTS: Of 167 patients, 13 (7.8%) developed POD. The MoCA-J Memory + Orientation composite score showed the highest predictive accuracy. In the multivariable analysis, a composite score < 7 (odds ratio [OR] = 12.81, 95% confidence interval [CI]: 1.95-84.0), older age (per year, OR = 1.10, 95% CI: 1.01-1.21), preexisting respiratory disease (OR = 7.82, 95% CI: 1.40-43.9), and intraoperative blood loss (per 100 ml increment, OR = 1.53, 95% CI: 1.05-2.25) were independently associated with POD. CONCLUSIONS: The MoCA-J domain-specific composite score for memory and orientation was the strongest predictor of POD, alongside established factors, such as older age, preexisting respiratory disease, and intraoperative blood loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rehabilitation Technology, Sakai City Medical Center, Sakai, Japan.
- Department of Gastrointestinal Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai, 5938304, Japan. r-kawabata@umin.ac.jp.
- Center for Geriatric Medical Management, Sakai City Medical Center, Sakai, Japan.
- Department of Gastrointestinal Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai, 5938304, Japan.
- Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan.
Zitieren
APA
Yamaguchi, H., Kawabata, R., Yoshiyama, S., Fujiwara, M., Matsukawa, N., Kitamura, M., Takeoka, T., Hara, H., Yoshihara, T., Kitagawa, A., Tomihara, H., Naito, A., Murakami, M., Shimomura, K., Noura, S., & Miyamoto, A. (2025). Montreal cognitive assessment domain-specific and clinical predictors of postoperative delirium in elderly gastrointestinal cancer patients. Surgery Today. https://doi.org/10.1007/s00595-025-03171-2
Vancouver
Yamaguchi H, Kawabata R, Yoshiyama S, Fujiwara M, Matsukawa N, Kitamura M, et al. Montreal cognitive assessment domain-specific and clinical predictors of postoperative delirium in elderly gastrointestinal cancer patients. Surgery Today. 2025. doi:10.1007/s00595-025-03171-2
BibTeX
@article{Yamaguchi2025,
author = {Yamaguchi, Haruna and Kawabata, Ryohei and Yoshiyama, Shiori and Fujiwara, Mamiko and Matsukawa, Norihisa and Kitamura, Masaru and Takeoka, Tomohira and Hara, Hisashi and Yoshihara, Terukazu and Kitagawa, Akihiro and Tomihara, Hideo and Naito, Atsushi and Murakami, Masahiro and Shimomura, Kazuhiro and Noura, Shingo and Miyamoto, Atsushi},
title = {Montreal cognitive assessment domain-specific and clinical predictors of postoperative delirium in elderly gastrointestinal cancer patients},
journal = {Surgery Today},
year = {2025},
doi = {10.1007/s00595-025-03171-2}
}
EUVIMED